Acumen Pharma posts smaller-than-expected 2025 loss on lower G&A costs
Overview
U.S. Alzheimer's drug developer's 2025 net loss and operating loss both narrower than analyst estimates
R&D expenses rose on higher costs for ALTITUDE-AD trial and pipeline expansion
Company raised $35.75 mln in March 2026 private placement to advance EBD program
Outlook
Company expects topline results from ALTITUDE-AD Phase 2 study in late 2026
Acumen targets IND filing for lead EBD program candidate in mid-2027
Cash expected to support clinical and operational activities into early 2027
Result Drivers
R&D SPENDING - Higher R&D expenses driven by increased manufacturing and materials costs for ALTITUDE-AD trial and EBD program expansion
COST CONTROL - Lower G&A expenses due to reductions in recruiting, insurance, and consulting costs
PIPELINE FUNDING - $35.75 mln private placement in March 2026 to advance EBD portfolio after strong preclinical data
Company press release: ID:nGNXbGVlZq
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income | Beat | -$121.34 mln | -$124.77 mln (6 Analysts) |
FY Income From Operations | Beat | -$123.83 mln | -$127.89 mln (6 Analysts) |
FY Basic EPS |
| -$2 |
|
FY Operating Expenses |
| $123.83 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $8.00, about 204.2% above its March 25 closing price of $2.63
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
